In Vivo Molecular Imaging for Biomedical Analysis and Therapies

Ogawa, Mikako; Takakura, Hideo

doi:10.2116/analsci.34.273

Cited by 15 publications

(9 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Using fluorescent reporter gene markers to detect the growth, migration labelled cells in living organisms is applied in many kinds of diseases in vivo. 30 Here, we used this technology to monitor the location of 4T1 tumour, and the results suggested that fluorescence imaging of 4T1 tumours in both TLR5 knock-down and negative control virus transfection was much clearer than no virus transfected 4T1 tumour, and with advantage for clearly tumour edge displaying. And more importantly, we found that the locations of fluorescence were tightly consisted with tracer radioactivity, which further proved that tumour image was TLR5 expression image specificity.…”

Section: Discussionmentioning

confidence: 92%

“…125 I‐IgG failed to target TLR5 accurately in tumour‐bearing mice, exhibiting non‐specific retention in tumours. Using fluorescent reporter gene markers to detect the growth, migration labelled cells in living organisms is applied in many kinds of diseases in vivo . Here, we used this technology to monitor the location of 4T1 tumour, and the results suggested that fluorescence imaging of 4T1 tumours in both TLR5 knock‐down and negative control virus transfection was much clearer than no virus transfected 4T1 tumour, and with advantage for clearly tumour edge displaying.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

TLR5 is a new reporter for triple‐negative breast cancer indicated by radioimmunoimaging and fluorescent staining

Shi

Liu

Zhao

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

Triple‐negative breast cancer (TNBC) is a highly aggressive tumour that lacks marker for targeted diagnosis. Recently, it was reported that toll‐like receptor 5 (TLR5) was associated with some kind of tumours, especially in TNBC, but whether it could be used as a non‐invasive monitoring target is not fully understood. Here, we established TLR5− 4T1 cell line with lentivirus‐shRNA‐TLR5 knock‐down transfection (with tag GFP, green fluorescent protein, TLR5− 4T1) and control TLR5+ 4T1 cell line with negative control lentivirus transfection. The effect of TLR5 down‐regulation was detected with qPCR and Western blot. 125I‐anti‐TLR5 mAb and control isotype 125I‐IgG were prepared and injected to TLR5+/− 4T1‐bearing mice models, respectively. Whole‐body phosphor‐autoradiography, fluorescence imaging and biodistribution were performed. Furthermore, ex vivo tumour TLR5 expression was proved through immunohistochemistry staining. We found that 125I‐anti‐TLR5 mAb could bind to TLR5+ 4T1 with high affinity and specificity. Whole‐body phosphor‐autoradiography after 125I‐anti‐TLR5 mAb injection showed TLR5+ 4T1 tumour images in 24 hours, more clearly in 48 hours. Radioactivities in tumour tissues were positively related with TLR5 expression. Biodistribution assay showed that 125I‐anti‐TLR5 mAb was mainly metabolized through the liver and kidney, and 125I‐anti‐TLR5 mAb was much more accumulated in TLR5+ 4T1 tumour than TLR5− 4T1. In vivo fluorescence imaging successfully showed tumour tissues clearly both in TLR5+ and TLR5− 4T1 mice compared with lentivirus untreated 4T1 tumour. Immunohistochemistry staining showed that TLR5 expression in tumours was indeed down‐regulated in TLR5− 4T1 mice. Our results indicated that 125I‐antiTLR5 mAb was an ideal agent for non‐invasive imaging of TLR5+ tumours; TLR5 may be as a novel molecular target for TNBC non‐invasive diagnosis.

show abstract

Section: Discussionmentioning

confidence: 92%

Section: Discussionmentioning

confidence: 99%

TLR5 is a new reporter for triple‐negative breast cancer indicated by radioimmunoimaging and fluorescent staining

Shi

Liu

Zhao

et al. 2019

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…Fluorescent reporter gene imaging in vivo has been applied to detect the growth and migration of labeled cells in many kinds of diseases 45 . Here, we monitored tumor locations using a TLR5 knockdown 4T1 cell line labeled with green fluorescent protein.…”

Section: Discussionmentioning

confidence: 99%

TLR5: A prognostic and monitoring indicator for triple-negative breast cancer

et al. 2019

View full text Add to dashboard Cite

A novel, highly selective biomarker is urgently needed to predict and monitor triple-negative breast cancer (TNBC) because targeting molecules are not currently available. Although associated with various malignant tumors, the role of toll-like receptor 5 (TLR5) in TNBC remains uncertain. We aimed to define the effects of TLR5 in TNBC to determine whether it could serve as a prognostic and monitoring indicator for TNBC. We established TNBC cell line 4T1 with low TLR5 expression (GFP tag; TLR5− 4T1) and with normal TLR5 expression (GFP tag; TLR5+ 4T1) using lentivirus-shRNA-TLR5 knockdown transfection and negative lentivirus transfection, respectively. Detected by western blot and qPCR, we found knockdown of TLR5 resulted in decreased expression of TLR5 and E-cadherin and increased expression of N-cadherin, vimentin, fibronectin, TRAF6, SOX2, and Twist1, which were related to EMT (epithelial–mesenchymal transition). In addition, downregulation of TLR5 increased the invasion and migration of 4T1 cells in vitro, which were investigated by CCK-8 and wound healing, as well as transwell assay and colony formation. Furthermore, the metastatic ability of TLR5− 4T1 cells to the lungs was also increased compared to TLR5+ 4T1 cells in vivo. To verify the effect of TLR5 as a monitor indicator, mice bearing TLR5+ and TLR5− 4T1 tumors injected with 125I-anti-TLR5 mAb or isotype 125I-IgG were assessed by whole body phosphor-autoradiography and fluorescence imaging in vivo. Phosphor-autoradiography of model mice revealed early tumors at 6 days after inoculation with TLR5+ 4T1, but not TLR5− 4T1 cells. Intratumoral accumulation of radioactivity positively correlated with TLR5 expression, and fluorescence imaging in vivo revealed both TLR5+ and TLR5− 4T1 tumors. Our results suggested that downregulation of TLR5 in TNBC increased tumor invasiveness and EMT expression via TRAF6 and SOX2 pathway and TLR5 could serve as a prognostic and monitoring indicator for TLR5-positive tumors.

show abstract

“…https://www.sgu.ru/structure/fiz/saratov-fall-meeting/previousconferences/sara приобретает оптический клеточный мониторинг (диэлектрофорез эритроцитов -направленное движение частиц в неоднородном переменном электрическом поле с их оптической детекцией) [2,3]. Метод точен, информативен, малоинвазивен и не требует трудоемкой подготовки образца, его данные хорошо дополняют данные оптических методов анализа, широко используемых в медицине, таких как раман-, ИК спектроскопия, люминесценция [4,5]. Целью настоящей работы явилось исследование возможностей оптической системы мониторинга эритроцитов на основе диэлектрофореза [6] для диагностики КРР.…”

unclassified

Новые возможности диагностики колоректального рака c помощью оптической системы детекции клеток на основе диэлектрофореза-=SUP=-*-=/SUP=-

Кручинина¹,

Прудникова²,

Gromov³

et al. 2019

Журнал Технической Физики

View full text Add to dashboard Cite

The possibilities of using electrical and viscoelastic parameters of erythrocytes in patients with colorectal cancer (CRC) of different stages were demonstrated using optical cell detection system based on the dielectrophoresis method. The deformation amplitude, portion of deformed cells, generalized viscosity, rigidity, equilibrium frequency position, and electrical conductivity were the most significant parameters for determining patients with CRC, as well as early and late stages, included in the created model of a riskometer for the disease diagnosis. The created diagnostic “panels” with a high diagnostic accuracy, sensitivity, and specificity allowed to one determine patients with CRC (specificity 0.91, sensitivity 0.96), as well as early and late stages of the disease (specificity 0.64, sensitivity 0.86).

show abstract

In Vivo Molecular Imaging for Biomedical Analysis and Therapies

Cited by 15 publications

References 76 publications

TLR5 is a new reporter for triple‐negative breast cancer indicated by radioimmunoimaging and fluorescent staining

TLR5 is a new reporter for triple‐negative breast cancer indicated by radioimmunoimaging and fluorescent staining

TLR5: A prognostic and monitoring indicator for triple-negative breast cancer

Новые возможности диагностики колоректального рака c помощью оптической системы детекции клеток на основе диэлектрофореза-=SUP=-*-=/SUP=-

Contact Info

Product

Resources

About